Heparin modulates the binding of insulin-like growth factor (IGF) binding protein-5 to a membrane protein in osteoblastic cells.
Osteoblast-like cells secrete insulin-like growth factor (IGF) binding protein-5 (IGFBP-5), which may act to enhance IGF-stimulated osteoblast function. We recently demonstrated that carboxyl-truncated IGFBP-5 (IGFBP-5(1-169)) binds to the osteoblast surface and stimulates mitogenesis by a pathway that is independent of IGF action. The present study was conducted to determine the mechanism of osteoblast binding of IGFBP-5, beginning with the assumption that cell surface glycosaminoglycans may mediate the binding of this heparin binding protein. Intact 125I-IGFBP-5 and 125I-IGFBP-5(1-169) exhibited one-site binding to mouse osteoblast monolayers with dissociation constants of 28 and 6 nM for intact 125I-IGFBP-5 and 125I-IGFBP-5(1-169), respectively. Osteoblast binding of intact 125I-IGFBP-5 was inhibited by low heparin concentrations, while 125I-IGFBP-5(1-169) binding was stimulated by heparin. Treatment of cells with heparinase or chlorate to decrease surface glycosaminoglycan density failed to reduce the binding of either form of IGFBP-5. In contrast, pretreatment of cells with IGFBP-5 caused down-regulation of 125I-IGFBP-5 binding. Cross-linking studies revealed that both intact 125I-IGFBP-5 and 125I-IGFBP-5(1-169) bind to proteins in Triton extracts of osteoblast membranes, which were absent in osteoblast-derived matrix. Purification of membrane extracts by IGFBP-5 affinity chromatography revealed a 420-kDa band on reduced SDS-polyacrylamide gels. While the membrane protein internalized both forms of IGFBP-5, heparin treatment inhibited the internalization of intact 125I-IGFBP-5 but stimulated 125I-IGFBP-5(1-169) internalization. These data indicate that IGFBP-5 binds to and is internalized by an osteoblast membrane protein, which does not appear to be a proteoglycan. Glycosaminoglycans, however, modulate the binding and internalization of IGFBP-5 in a way that may preferentially favor the intracellular accumulation of the carboxyl-truncated form.
D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D002460:Cell Line; D002846:Chromatography, Affinity; D003432:Cross-Linking Reagents; D005109:Extracellular Matrix / Q000378:metabolism / Q000648:ultrastructure; D006025:Glycosaminoglycans / Q000378:metabolism / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology*; D019763:Heparin Lyase; D018975:Insulin-Like Growth Factor Binding Protein 5 / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D007457:Iodine Radioisotopes; D007700:Kinetics; D008565:Membrane Proteins / Q000302:isolation & purification / Q000378:metabolism*; D051379:Mice; D008969:Molecular Sequence Data; D010006:Osteoblasts / Q000378:metabolism*; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000494:pharmacology; D011133:Polysaccharide-Lyases / Q000494:pharmacology; D011994:Recombinant Proteins / Q000378:metabolism; D018411:Spodoptera; D014162:Transfection
D003432:Cross-Linking Reagents; D006025:Glycosaminoglycans; D018975:Insulin-Like Growth Factor Binding Protein 5; D007457:Iodine Radioisotopes; D008565:Membrane Proteins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D006493:Heparin; D011133:Polysaccharide-Lyases; D019763:Heparin Lyase